Director/PDMR Shareholding

RNS Number : 3464D
Oxford Biomedica PLC
22 March 2011





Oxford, UK - 22 March 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, has been notified that Dr Alan Kingsman, Chairman of the Company, has transferred part of his interest in Oxford BioMedica plc 1p ordinary shares, comprising 10,293,451 shares, into a designated nominee account.  There is no change to his overall interest in shares, which remains at 15,032,590 shares representing 1.59% of the current issued share capital of the Company.




For further information, please contact:

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tel: +44 (0)1865 783 000


Media Enquiries:

Emma Thompson/Amber Bielecka/Katja Toon



Tel: +44 (0)20 7920 2342



Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at

This information is provided by RNS
The company news service from the London Stock Exchange